|
Cytokinetics Announces Clinical Trials Data to be Presented at the 2008 Annual Meeting of the American Society of Clinical Oncology
(Marketwire Via Acquire Media NewsEdge) SOUTH SAN FRANCISCO, CA, May 16 / MARKET WIRE/ --
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that three abstracts summarizing data from clinical
trials relating to its oncology programs are planned to be presented at the
2008 Annual Meeting of the American Society of Clinical Oncology (ASCO) in
Chicago, IL, May 30-June 3, 2008. Two of these abstracts relate to
clinical trials evaluating ispinesib that are sponsored by Cytokinetics or
the National Cancer Institute (NCI). The third abstract relates to a
clinical trial evaluating SB-743921 that is sponsored by Cytokinetics.
Ispinesib and SB-743921 are novel, chemically distinct, small molecule
inhibitors of kinesin spindle protein (KSP), a mitotic kinesin essential
for proper cell division. Both drug candidates have arisen from a broad
strategic collaboration between Cytokinetics and GlaxoSmithKline (GSK) to
discover, develop and commercialize novel small molecule therapeutics
targeting human mitotic kinesins for applications in the treatment of
cancer and other diseases.
Presentations at ASCO
The following abstracts are planned to be presented at ASCO. These
abstracts are available through the ASCO website (www.asco.org):
Oral Presentation:
Abstract #10014: Pediatric Phase I Trial and Pharmacokinetic (PK) study of
ispinesib (SB-715992): A Children's Oncology Group Phase I Consortium
Study. (Oral presentation by Abdul-Kader Souid, MD, PhD, SUNY Upstate
Medical University, Syracuse, NY, on Sunday, June 1, 2008, Pediatric Cancer
II; S100b, 8:00 AM - 11:00 AM).
Poster Presentations:
Abstract #1143: A Phase I-II Open-Label Trial of Ispinesib on an Alternate
Dosing Schedule in Chemotherapy-Naive Patients with Locally Advanced or
Metastatic Breast Cancer (MBC). (Poster presentation by Manuel Philco, MD,
Hospital Nacional Alberto Sabogal Solog?ren, Lima, Peru on Monday, June 2,
2008, Breast Cancer - Metastatic, General Poster Session, S Hall A1, Poster
#48D, 2:00 PM - 6:00 PM).
Abstract #8539: A Phase I-II trial of the Kinesin Spindle Protein (KSP)
Inhibitor SB-743921 on Days 1 and 15 Every 28 Days in Non-Hodgkin or
Hodgkin Lymphoma. (Poster discussion by Owen O'Connor, MD, PhD., Columbia
Medical Center, New York, N.Y. on Tuesday, June 3, 2008, Lymphoma and
Plasma Cell Disorders, Poster Discussion, E450a, Poster #14, 8:00 AM -
12:00 PM).
About Cytokinetics
Cytokinetics is a biopharmaceutical company focused on the discovery,
development and commercialization of novel small molecule drugs that may
address areas of significant unmet clinical needs. Cytokinetics'
development activities are primarily directed to advancing multiple drug
candidates through clinical trials with the objective of determining the
intended pharmacodynamic effect or effects in two principal diseases: heart
failure and cancer. Cytokinetics' cardiovascular disease program is focused
to cardiac myosin, a motor protein essential to cardiac muscle contraction.
Cytokinetics' lead compound from this program, CK-1827452, a novel small
molecule cardiac myosin activator, entered Phase II clinical trials for the
treatment of heart failure in 2007. Under a strategic alliance established
in 2006, Cytokinetics and Amgen Inc. are performing joint research focused
on identifying and characterizing activators of cardiac myosin as back-up
and follow-on potential drug candidates to CK-1827452. Amgen has obtained
an option for an exclusive license to develop and commercialize CK-1827452,
subject to Cytokinetics' development and commercial participation rights.
Cytokinetics' cancer program is focused on mitotic kinesins, a family of
motor proteins essential to cell division. Under a strategic alliance
established in 2001, Cytokinetics and GlaxoSmithKline (GSK) are conducting
research and development activities focused on the potential treatment of
cancer. Cytokinetics is developing two novel drug candidates that have
arisen from this program, ispinesib and SB-743921, each a novel inhibitor
of kinesin spindle protein (KSP), a mitotic kinesin. Cytokinetics believes
that ispinesib has demonstrated clinical activity in Phase II monotherapy
clinical trials in breast cancer, ovarian cancer and non-small cell lung
cancer and recently initiated an additional Phase I/II clinical trial of
ispinesib as monotherapy as a first-line treatment in chemotherapy-na?ve
patients with locally advanced or metastatic breast cancer on a more
dose-dense schedule than previously studied. Cytokinetics is also
conducting a Phase I/II trial of SB-743921 on a similar more dose-dense
schedule in
non-Hodgkin and Hodgkin lymphomas. GSK has obtained an option for the joint
development and commercialization of ispinesib and SB-743921. Cytokinetics
and GSK are conducting collaborative research activities directed to the
mitotic kinesin centromere-associated protein E (CENP-E). GSK-923295, a
CENP-E inhibitor, is being developed under the strategic alliance by GSK,
subject to Cytokinetics' option to co-fund certain later-stage development
activities and to co-promote any resulting approved drug in North America.
GSK began a Phase I clinical trial with GSK-923295 in 2007. In April 2008,
Cytokinetics announced the selection of a potential drug candidate directed
towards skeletal muscle contractility which may be developed as a potential
treatment for skeletal muscle weakness associated with neuromuscular
diseases or other conditions. All of these drug candidates and potential
drug candidates have arisen from Cytokinetics' research activities and are
directed towards the cytoskeleton. The cytoskeleton is a complex biological
infrastructure that plays a fundamental role within every human cell.
Cytokinetics' focus on the cytoskeleton enables it to develop novel and
potentially safer and more effective classes of drugs directed at
treatments for cancer and cardiovascular and other diseases. Additional
information about Cytokinetics can be obtained at www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Safe Harbor for
forward-looking statements contained in the Act. Examples of such
statements include, but are not limited to, statements relating to
Cytokinetics' and its partners' research and development activities,
including the presentation of data from clinical trials, the potential
benefits of Cytokinetics' drug candidates and potential drug candidates and
the enabling capabilities of Cytokinetics' cytoskeletal focus. Such
statements are based on management's current expectations, but actual
results may differ materially due to various risks and uncertainties,
including, but not limited to, potential difficulties or delays in the
development, testing, regulatory approval or production of Cytokinetics'
drug candidates that could slow or prevent clinical development, product
approval, including risks that current and past results of clinical trials
or preclinical studies may not be indicative of future clinical trials
results, patient enrollment for clinical trials may be difficult or
delayed, Cytokinetics' drug candidates may have adverse side effects or
inadequate therapeutic efficacy, the U.S. Food and Drug Administration or
foreign regulatory agencies may delay or limit Cytokinetics' or its
partners' ability to conduct clinical trials, and Cytokinetics may be
unable to obtain or maintain patent or trade secret protection for its
intellectual property; GSK may decide to postpone or discontinue
development activities for GSK-923295, Cytokinetics may incur unanticipated
research and development and other costs or be unable to obtain additional
financing necessary to conduct development of its products, standards of
care may change, others may introduce products or alternative therapies for
the treatment of indications Cytokinetics' drug candidates and potential
drug candidates may target, and risks and uncertainties relating to the
timing and receipt of payments from our partners, including milestones and
royalties on future potential product sales under Cytokinetics'
collaboration agreements with such partners. For further information
regarding these and other risks related to Cytokinetics' business,
investors should consult Cytokinetics' filings with the Securities and
Exchange Commission.
Contacts:
Scott R. Jordan (Media)
Director, Corporate Development
(650) 624-3000
Christopher S. Keenan (Investors)
Director, Investor Relations
(650) 624-3000
Copyright ? 2008 Marketwire
[ Back To TMCnet.com's Homepage ]
|
INDUSTRIES
Activate Email 
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO East, January 20-22, 2010. Miami, FL.
